QNTM

Quantum Biopharma Ltd

Add to Watchlist

Advanced Chart

29.210

+3.2(12.303%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

29.245

Open

27.810

VWAP

27.96

Vol

217.28K

Mkt Cap

111.46M

Low

26.940

Amount

6.07M

EV/EBITDA(TTM)

Total Shares

3.82M

109.55M

EV/OCF(TTM)

P/S(TTM)

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

Valuation Metrics

The current forward P/E ratio for Quantum Biopharma Ltd (QNTM.O) is 0.00, compared to its 5-year average forward P/E of -1.71. For a more detailed relative valuation and DCF analysis to assess Quantum Biopharma Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.71

Current PE

0.00

Overvalued PE

0.93

Undervalued PE

-4.35

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.68

Current PS

0.57

Overvalued PS

1.56

Undervalued PS

-0.19

Financials

Annual

Quarterly

FY2025Q2

N/A

Total Revenue

FY2025Q2

YoY :

+40.41%

-4.85M

Operating Profit

FY2025Q2

YoY :

+191.31%

-9.77M

Net Income after Tax

FY2025Q2

YoY :

-41.49%

-3.06

EPS - Diluted

FY2025Q2

YoY :

+221.38%

-1.95M

Free Cash Flow

FY2025Q2

N/A

Gross Profit Margin - %

FY2025Q2

N/A

FCF Margin - %

FY2025Q2

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

QNTM News & Events

Events Timeline

2025-08-08 (ET)

2025-08-08

08:09:26

Quantum BioPharma announces results from study on PET tracer

2025-08-07 (ET)

2025-08-07

07:14:39

Quantum Group reports Q2 operating expenses $4.9M vs $3.4M last quarter

2025-08-05 (ET)

2025-08-05

07:36:57

Quantum Group subsidiary received CSR for Phase 1 MAD trial

News

9.5

08-07Newsfilter

Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of date of filing, and Near Elimination of Debt

9.0

08-05Benzinga

Quantum Biopharma Reports Positive Phase 1 Safety For Multiple Sclerosis Drug

9.0

08-05Newsfilter

Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)